Reprogrammed Interchange Llc Sells 2,021 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold 2,021 shares of Vor Biopharma stock at an average price of $30.45, totaling approximately $61,539.45, which decreased their ownership in the company by 0.17%.
• Vor Biopharma's stock has seen significant fluctuations, trading down to $29.00, with a twelve-month range of $2.62 to $65.80.
• Analyst ratings for Vor Biopharma are mixed, with upgrades to a "buy" and "strong-buy" while it holds a consensus rating of "Hold" and a price target of $77.83.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $30.45, for a total transaction of $61,539.45. Following the transaction, the insider directly owned 1,204,442 shares of the company's stock, valued at approximately $36,675,258.90. This trade represents a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The shares were sold at an average price of $31.92, for a total transaction of $2,287,227.60.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The shares were sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The shares were sold at an average price of $33.87, for a total value of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total value of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The stock was sold at an average price of $37.01, for a total value of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.

Vor Biopharma Trading Down 0.2%

Shares of VOR traded down $0.06 during midday trading on Friday, reaching $29.00. 613,740 shares of the stock were exchanged, compared to its average volume of 395,121. The firm has a 50 day moving average of $36.55. The stock has a market capitalization of $198.65 million, a P/E ratio of -0.11 and a beta of 2.07. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Analyst Ratings Changes

Several equities research analysts recently issued reports on VOR shares. Stifel Nicolaus upgraded Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price target for the company in a research note on Wednesday, September 24th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th. Robert W. Baird raised shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $20.00 to $64.00 in a research report on Wednesday. Finally, Baird R W raised shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $77.83.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the second quarter valued at about $66,000. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares during the period. Jane Street Group LLC acquired a new position in Vor Biopharma in the 1st quarter valued at approximately $140,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma during the first quarter worth $100,000. Finally, Money Concepts Capital Corp grew its stake in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.